Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib in HER2-positive Refractory Advanced Cancer
NCT02342587Phase 2Completed
- Sponsor
- Samsung Medical Center
- Start
- Dec 2014
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lapatinib in HER2-positive solid tumor (HER2+), sponsored by Samsung Medical Center. Primary endpoint: Overall Response Rate at 4 weeks. Started Dec 2014; status: completed.
02
Drugs
lapatinib
03
Conditions
HER2-positive solid tumor (HER2+)
Beyond the preview
Go deeper on NCT02342587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02342587.